Avenue Therapeutics, Inc. (ATXI) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAvenue Therapeutics, Inc. (ATXI) trades at $0.30. Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing intravenous Tramadol for acute pain management in hospital settings. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for ATXI: ATXI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Avenue Therapeutics, Inc. (ATXI) Healthcare & Pipeline Overview
Avenue Therapeutics, Inc. specializes in developing innovative pharmaceutical solutions for acute pain management, leveraging its proprietary intravenous Tramadol to target unmet medical needs in intensive care settings, positioning itself uniquely within the biotechnology sector.
What Is the Investment Thesis for ATXI?
Avenue Therapeutics, Inc. presents a unique investment thesis driven by its innovative product pipeline, particularly the intravenous Tramadol, which is in Phase III clinical trials. The potential market for acute pain management is substantial, with a growing emphasis on effective post-operative care solutions. If successful, the product could capture a significant share of the estimated $3 billion U.S. market for post-operative pain management. Key value drivers include the increasing demand for opioid alternatives and the company's focused strategy on acute care settings. However, risks include the challenges associated with clinical trial outcomes and regulatory approvals, which could affect timelines and market entry. Overall, Avenue Therapeutics is positioned to leverage its specialized focus to address critical pain management needs, making it an intriguing prospect for investors interested in the biotechnology sector.
Based on FMP financials and quantitative analysis
ATXI Key Highlights
Market Cap: $0.00B, indicating a nascent stage in market presence.
- Profit Margin: -124.8%, reflecting the early-stage nature of the company's financials.
- Beta: -0.08, suggesting lower volatility compared to the broader market.
- Dividend Yield: None, as the company is reinvesting in its clinical development.
- Employee Count: 2, indicating a lean operational structure focused on product development.
Who Are ATXI's Competitors?
ATXI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| PFE Pfizer Inc. | $28.06 | -1.44% | $160B | 67 5-pillar |
| AMGN Amgen Inc. | $443.89 | -3.07% | $240B | 84 5-pillar |
| JNJ Johnson & Johnson | $272.70 | -2.15% | $656B | 83 5-pillar |
| RLYB Rallybio Corporation | $15.26 | -0.20% | $85.5M | 82 5-pillar |
| ICCC ImmuCell Corporation | $11.25 | -0.71% | $102M | 82 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $3.89 | +0.52% | $169M | 72 5-pillar |
| CGEN Compugen Ltd. | $1.88 | -4.08% | $178M | 69 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $3.06 | +1.32% | $258M | 90 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ATXI's Key Strengths?
Focused expertise in acute pain management.
- Innovative product candidate in clinical trials.
- Strong potential market demand for effective pain relief solutions.
What Are ATXI's Weaknesses?
Limited financial resources with a small employee base.
- High dependency on successful clinical trial outcomes.
- No current revenue streams, relying on future product commercialization.
What Could Drive ATXI Stock Higher?
Results from Phase III clinical trials for intravenous Tramadol expected in 2026.
- Development of strategic partnerships with healthcare institutions.
- Potential regulatory submissions for intravenous Tramadol following trial results.
What Are the Key Risks for ATXI?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Delays in clinical trial timelines impacting market entry.
- Competition from established pharmaceutical companies in pain management.
- Regulatory hurdles that could affect product approval.
What Are the Growth Opportunities for ATXI?
- Growth opportunity 1: The intravenous Tramadol market is projected to grow significantly as hospitals seek effective pain management solutions. The U.S. acute pain management market is estimated to reach $3 billion by 2028, driven by the increasing number of surgical procedures and the demand for opioid alternatives. Avenue Therapeutics is strategically positioned to capture market share as it advances its product through clinical trials.
- Growth opportunity 2: The ongoing opioid crisis has heightened the demand for safer pain management alternatives, creating a favorable environment for Avenue Therapeutics' intravenous Tramadol. As healthcare providers look for effective yet non-addictive pain relief options, the company stands to benefit from increased adoption of its product upon successful commercialization.
- Growth opportunity 3: Partnerships with healthcare institutions and pain management specialists can enhance Avenue Therapeutics' market reach. Collaborating with key opinion leaders in pain management may facilitate clinical trial recruitment and increase awareness of intravenous Tramadol's benefits, potentially accelerating its path to market.
- Growth opportunity 4: Expansion into international markets presents a significant opportunity for Avenue Therapeutics. As global healthcare systems evolve and prioritize effective pain management, the company can explore licensing agreements or partnerships to introduce its product in regions with high surgical volumes and unmet pain management needs.
- Growth opportunity 5: The development of additional formulations or indications for intravenous Tramadol could broaden Avenue Therapeutics' product portfolio. By exploring its use in various acute pain scenarios or in combination with other therapies, the company may enhance its value proposition and capture a larger share of the pain management market.
What Threats Does ATXI Face?
- Regulatory hurdles in drug approval processes.
- Intense competition from established pharmaceutical companies.
- Market volatility affecting funding and investment opportunities.
What Are ATXI's Competitive Advantages?
- Focus on a specialized product for acute pain management, differentiating from broader pharmaceutical companies.
- Innovative drug formulation targeting unmet needs in the hospital setting.
- Potential to establish strong relationships with healthcare providers and institutions.
- Advantage of a lean operational structure allowing for agile decision-making.
- Commitment to addressing the opioid crisis through safer pain management options.
What Does ATXI Do?
Avenue Therapeutics, Inc. was founded in 2015 and is headquartered in New York City, United States. The company is dedicated to the development and commercialization of pharmaceutical products specifically designed for use in acute and intensive care hospital environments. Avenue Therapeutics is primarily focused on its lead product candidate, intravenous Tramadol, a synthetic dual-acting opioid that is currently undergoing Phase III clinical trials aimed at treating post-operative acute pain. This innovative approach addresses a critical gap in pain management, particularly for patients who require effective analgesia following surgical procedures. The company’s commitment to improving patient outcomes in acute care settings is evident in its research and development efforts, which are geared towards bringing this important therapeutic option to market. Avenue Therapeutics operates with a small team of two employees, reflecting its focused strategy on advancing its clinical programs and establishing partnerships within the healthcare sector. As it navigates the complexities of drug development, Avenue Therapeutics is positioned to make a significant impact in the field of pain management, particularly as healthcare systems increasingly seek effective solutions for acute pain relief in hospital settings.
What Products and Services Does ATXI Offer?
- Develops intravenous Tramadol for acute pain management.
- Focuses on the hospital and intensive care settings.
- Conducts clinical trials to validate product efficacy.
- Seeks to address unmet needs in post-operative pain relief.
- Aims to provide a safer alternative to traditional opioids.
- Engages in partnerships to enhance product development and market reach.
How Does ATXI Make Money?
- Generates revenue through the commercialization of pharmaceutical products.
- Focuses on developing innovative therapies for acute care settings.
- Plans to partner with healthcare institutions for clinical trials and product adoption.
- Aims to capture market share in the growing acute pain management market.
- Explores licensing agreements for international market entry.
What Industry Does ATXI Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in drug development and an increasing focus on personalized medicine. The acute pain management market, particularly in hospital settings, is projected to expand significantly, fueled by the rising incidence of surgical procedures and the need for effective pain relief solutions. Avenue Therapeutics, with its focus on intravenous Tramadol, is well-positioned to capitalize on these trends, targeting a niche that is increasingly recognized as vital for patient care. As healthcare providers seek alternatives to traditional opioids, Avenue's innovative approach may provide a competitive edge in a crowded market.
Who Are ATXI's Key Customers?
- Hospitals and healthcare systems requiring effective pain management solutions.
- Surgeons and medical professionals involved in post-operative care.
- Patients undergoing surgical procedures needing acute pain relief.
- Healthcare providers seeking alternatives to traditional opioid therapies.
- Pharmaceutical partners for potential collaborations and licensing.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
Insider Activity
12 transactions · 2 purchases, 2 sales, 8 other transactions · 7 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Forward Outlook
Wall Street analysts project Avenue Therapeutics, Inc. revenue of about $1.4M for fiscal 2026, with EPS near $-1.84.
Earnings Track Record
Avenue Therapeutics, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 95.2% above estimates on average.
Financial Health
Avenue Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Company Profile
Avenue Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Bay Harbor Islands, US. The company is led by CEO Alexandra MacLean. ATXI has traded publicly since 2017.
ATXI Financials
Bull Case vs Bear Case
Bull Case
- Focused expertise in acute pain management.
- Innovative product candidate in clinical trials.
- Strong potential market demand for effective pain relief solutions.
- Upcoming: Results from Phase III clinical trials for intravenous Tramadol expected in 2026.
Bear Case
- Limited financial resources with a small employee base.
- High dependency on successful clinical trial outcomes.
- No current revenue streams, relying on future product commercialization.
- Potential: Delays in clinical trial timelines impacting market entry.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026
ATXI Latest News
No recent news available for ATXI.
ATXI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ATXI.
Price Targets
Wall Street price target analysis for ATXI.
ATXI MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ATXI; grades run from A+ (80-100) to F (below 30).
Leadership: Alexandra MacLean
CEO
Alexandra MacLean has a robust background in pharmaceutical development and management. She has held various leadership roles in the healthcare sector, focusing on product development and strategic planning. Her education includes a degree in a relevant field, equipping her with the knowledge to lead Avenue Therapeutics effectively.
Track Record: Under Alexandra's leadership, Avenue Therapeutics has made significant strides in advancing its intravenous Tramadol through clinical trials. Her strategic decisions have positioned the company to address critical pain management needs in acute care settings.
ATXI OTC Market Information
The OTC Other tier includes securities that are not listed on a national exchange like NYSE or NASDAQ. Companies in this tier may have less stringent reporting requirements, which can lead to less visibility and liquidity compared to those on major exchanges.
- OTC Tier: OTC Other
- Limited financial transparency due to OTC classification.
- Potential for lower liquidity impacting trading activities.
- Regulatory risks associated with drug development and approval processes.
- Verify the status of clinical trials and regulatory submissions.
- Research the competitive landscape and market potential for intravenous Tramadol.
- Assess the company's financial health and funding requirements.
- Evaluate potential partnerships or collaborations in the healthcare sector.
- Review any recent news or developments related to Avenue Therapeutics.
- Incorporated in 2015, indicating a commitment to long-term goals.
- Focus on addressing unmet medical needs in acute pain management.
- Engagement in clinical trials to validate product efficacy.
ATXI Healthcare Stock FAQ
Is ATXI a good stock to buy?
Stock Expert AI does not rate ATXI buy, sell or hold. Avenue Therapeutics, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ATXI stock price today?
The last price recorded on this page for Avenue Therapeutics, Inc. (ATXI) is $0.30, as of the Nov 19, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is Avenue Therapeutics, Inc.'s drug pipeline status?
Avenue Therapeutics is currently advancing its lead product candidate, intravenous Tramadol, which is in Phase III clinical trials for treating post-operative acute pain. The outcome of these trials will be critical in determining the product's future in the market.
What are the key factors to evaluate for ATXI?
Evaluate ATXI on fundamentals, analyst consensus, and risk factors. Avenue Therapeutics, Inc. presents a unique investment thesis driven by its innovative product pipeline, particularly the intravenous Tramadol, which is in Phase III clinical trials. Not financial advice.
How frequently does ATXI data refresh on this page?
ATXI's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ATXI's recent stock price performance?
Avenue Therapeutics, Inc. (ATXI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focused expertise in acute pain management. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ATXI overvalued or undervalued right now?
Avenue Therapeutics, Inc. (ATXI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ATXI before investing?
Before investing in Avenue Therapeutics, Inc. (ATXI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Limited financial transparency due to OTC classification.